Cosmo Pharmaceuticals Nv · SIX:COPN
Cosmo Pharmaceuticals Nv — FY2020 Earnings Presentation
30 slides from Cosmo Pharmaceuticals Nv's earnings presentation, March 2021
Slide 1: Cosmo Pharmaceuticals Full Year Report 2020
e COSMO Pharmaceuticals FULL YEAR REPORT 2020 Cosmo Pharmaceuticals
Slide 2: Safe Harbour
SAFE HARBOUR This presentation may include forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. The inclusion of forward-looking statements should not be regarded as a representation by Cosmo that any of its p
Slide 3: Agenda
AGENDA 01. Introduction Alessandro Della Cha, CEO 02 2020 Key Events & Products Update Niall Donnelly, CFO Q3 2020 Financial Review Niall Donnelly, CFO 04 2021 Key Priorities & Outlook Alessandro Della Cha, CEO Cosmo Pharmaceuticals 3 Full Year Report 2020
Slide 4: Introduction
e Pee het Introduction Cosmo Pharmaceuticals 4 Full Year Report 2020
Slide 5: Financial Highlights
FINANCIAL HIGHLIGHTS Revenue €60.9m 2019: €62.5m Manufacturing of own products and related services €32.8m 2019: €28.7m Manufacturing of generic products and related services €10.8m 2019: €9.6m Royalties €8.5m 2019: €10.4m Licence fees, up-front fees and milestones €7.4m 2019: €12.5m ‘Cosmo Pharmace
Slide 6: Cosmo Overview
COSMO OVERVIEW Two marketed medtech products Eleview® GI Genius™ (EU) One approved therapeutic Methylene Blue MMX®(EU) Cosmo Pharmaceuticals Three marketed therapeutics Lialda® /Mezavant® Uceris®/Cortiment® Aemcolo®/RelaFalk® Rich development pipeline Market Cap* CHF 1,321.8 million Net Cash? €212.9
Slide 7: Cosmo's Stakes in Other Companies as a Result of Partnerships and Spin-offs
COSMO’S STAKES IN OTHER COMPANIES AS A RESULT OF PARTNERSHIPS AND SPIN-OFFS ¢ As at 31% of December 2020 the market value of our stakes in other companies, cash, loans, investments and treasury shares was €624.6 million. €M 2020 Shareholding in Cassiopea 224.7 Shareholding in Acacia Pharma Group plc
Slide 8: Commercialisation Through Partnerships
COMMERCIALISATION THOUGH PARTNERSHIPS ( cys > Ghire Lialda (mesalamin 2g \ ) ( r % FERRING| | 6 PHARMACEUTICALS co RTIMENT® r GIULIANI 4 ig MESAVANCOL \ ) (~ >) Receinm Biopharma L 2) Aemcolo \ ve Cosmo Pharmaceuticals cr ~ BAUSCH- Health { Ouceris \ J , morn) mesalazina 1200 mg NOGRA PHARMA aul cen
Slide 9: Commercialisation Through Partnerships
COMMERCIALISATION THOUGH PARTNERSHIPS \ ) v _ ane Medtronic (y Preece 4 Ciumesiue Me ys ir ~ aera, = Medtronic ; Elevi XY ot (<8) EA Pharma Co.,Ltd. — % S (— “th acacia — byfi ft yfavo.. \ es Cosmo Pharmaceuticals 9 Full Year Report 2020
Slide 10: Key Events & Products Update
® iene ae Key Events & Products Update Cosmo Pharmaceuticals
Slide 11: Key Events
KEY EVENTS * BYFAVO™ sub-licensed to Acacia Pharma Group (EURONEXT: ACPH) in an equity for product deal, BYFAVO™ subsequently approved by the FDA ° Very positive results of the first investigator initiated prospective clinical study of Gl Genius™ announced, ADR (Adenoma Detection Rate) and APC (Aden
Slide 12: Key Events
KEY EVENTS BYFAVO™ receives FDA approval for procedural sedation * Protocol and related statistical analysis plan for the Methylene Blue MMX® confirmatory phase III trial filed with the U.S. FDA for final comment * Cosmo's associate Cassiopea receives (FDA) approval for Winlevi® (clascoterone cream
Slide 13: Key Events
KEY EVENTS * License agreement with Dr. Falk Pharma Gmbh (“Dr. Falk”) amended in November to include Rifamycin SV MMX in the new 600mg formulation * Chinese rights for Lumeblue™ (Methylene Blue MMX®) licensed to China Medical System Holdings Ltd. (“CMS”) (SEHK: 867) in December * Successful outcome
Slide 14: Acacia Pharma Deal
ACACIA PHARMA DEAL * Acacia Pharma is an English company with U.S. operations listed on Euronext (EURONEXT: ACPH) run by a management team highly experienced in U.S. hospital sales ° Sublicense of BYFAVO™ for the U.S. in January, Acacia take over all marketing activities, development responsibilitie
Slide 15: Products Update: Methylene Blue MMX
PRODUCTS UPDATE Methylene Blue MMX® * In August, the European Commission approved Methylene Blue MMX® for the visualization of colorectal lesions during colonoscopies * In December, we licensed the Chinese rights for Lumeblue™ to China Medical System Holdings Ltd. (“CMS”) (SEHK: 867) ¢ |n February 2
Slide 16: Products Update: Aemcolo
PRODUCTS UPDATE Aemcolo™ * In January 2021, we announced the successful outcome of our Phase II Proof of Concept (POC) clinical trial of Rifamycin-MMxX 600mg in Irritable Bowel Syndrome with Diarrhea (IBS-D) * Together with our licensees, we will immediately commence discussions with the U.S. and EU
Slide 17: Products Update: GI Genius
PRODUCTS UPDATE GI Genius™ ° The U.S. trial required for FDA approval is ongoing * Sales in U.S. are expected to begin immediately after U.S. approval (scheduled within 1H 2021) * Europe, Australia, Israel and the United Arab Emirates regulatory approvals obtained so far * Sales in Europe commenced
Slide 18: GI Genius
GI Genius™ Cosmo Pharmaceuticals 18 Full Year Report 2020
Slide 19: 2020 Financial Review
10 Pharmaceuticals ® oe 2020 Financial Review
Slide 20: 2020 Financial Highlights
2020 FINANCIAL HIGHLIGHTS * Revenue €60.9m vs €62.5m last year ° Expenses reduced by €20.8m to €54.0m mainly as a result of the closure of our U.S. organization during 2019 and a gain on the sub-licencing of BYFAVO™, expenses include ESOP costs of €9.0m and Depreciation & Amortisation €6.0m * Operat
Slide 21: Income Statement - Revenue
INCOME STATEMENT - REVENUE * Revenue €60.9m vs €62.5m last year * — Lialda/Mesavant/Measvancol revenue increased by €5.9 million to €27.6m * Uceris income was €4.9m (2019: €9.3m), net sales by Bausch were USS$34.1m (2019: USS66.1m) * Cortiment income was €6.7m (2019: €3.9m) net sales by Ferring were
Slide 22: Income Statement
INCOME STATEMENT EUR 1,000 2020 2019 Change Revenue 60,949 62,495 (1,546) ° Revenue €60.9m vs €62.5m last year Other income 5,848 753 5,095 * Expenses reduced by €20.8m to €54.0m mainly as a Cost of sales (C7) BS (2,564) result of the closure of our U.S. organization during Research and development
Slide 23: Statement of Financial Position - Summary
STATEMENT OF FINANCIAL POSITION - SUMMARY EUR 1,000 2020 2019 Change Cash and cash equivalents and investments in funds 212,852 268,209 (55,357) Other current & non-current assets 383,309 316,951 66,358 Liabilities (196,036) (191,427) (4,609) Total Equity 400,125 393,733 6,392 * Cash and investments
Slide 24: Statement of Financial Position - Summary
STATEMENT OF FINANCIAL POSITION - SUMMARY Total Assets Total liabilities €596.1m €196.0m ‘Cosmo Pharmaceuticals 24 Full Year Report 2020
Slide 25: Cashflow
CASHFLOW EUR 1,000 FY 2020 Cashflow from operating activities 10,116 Acacia equity investment (20,000) Loan to Acacia (25,000) Purchase of treasury shares (5,721) Convertible bond interest (4,376) Capital expenditure (4,120) Participation in Cassiopea capital increase (4,122) Capitalised development
Slide 26: 2021 Key Priorities & Outlook
e AS ales 2021 Key Priorities & Outlook
Slide 27: Key Priorities for 2021
KEY PRIORITIES FOR 2021 * Complete the U.S. trial for Gl Genius™ and start sales * Have Cassiopea enter into a strategic deal to launch Winlevi® * Commence the Methylene Blue MMX® confirmatory phase III trial required for U.S. approval * Together with our licensees RedHill and Dr. Falk, commence dis
Slide 28: 2021 Guidance
2021 GUIDANCE The coronavirus pandemic will likely continue to impact Aemcolo™ and Eleview® sales and delay our clinical trials Guidance is based on obtaining FDA approval for GI Genius™ in H1 2021 and assumes an increase in costs associated with the deployment of G! Genius machines to Medtronic and
Slide 29: Thank You
e COSMO Pharmaceuticals Thank You Cosmo Pharmaceuticals
Slide 30: Cosmo Pharmaceuticals NV
Cosmo Pharmaceuticals NV Riverside II Sir John Rogerson’s Quay Dublin 2, Ireland media@cosmopharma.com Mr. Alessandro Della Cha, CEO adellacha@cosmopharma.com Mr. Niall Donnelly, CFO ndonnelly@cosmopharma.com Cosmo Pharmaceuticals 30 Full Year Report 2020